[Skip to Content]
[Skip to Content Landing]
May 1962

Glucose-6-Phosphate Levels and Liver Glycogen Disease

Author Affiliations

Joseph E. Sokal, Roswell Park Memorial Institute, 666 Elm St., Buffalo 3, N.Y.; From the Division of Medicine, Roswell Park Memorial Institute, New York State Department of Health, and the Statler Research Laboratories of the Children's Hospital and the Department of Pediatrics, the University of Buffalo School of Medicine.; Chief Cancer Research Internist, Roswell Park Memorial Institute, and Research Professor of Physiology (Dr. Sokal); Senior Cancer Research Scientist, Roswell Park Memorial Institute, and Associate Professor of Medicinal Chemistry (Dr. Sarcione); Research Assistant, Department of Pediatrics (Dr. Mosovich); Research Professor of Pediatrics (Dr. Lowe), University of Buffalo.

Am J Dis Child. 1962;103(5):678-681. doi:10.1001/archpedi.1962.02080020693007

Many congenital metabolic disorders can be diagnosed by a relatively simple blood or urine test. Furthermore, in some recessive hereditary diseases, asymptomatic heterozygous carriers can be identified by appropriate biochemical procedures. Recently, Hsia and Kot1 reported that identification of patients with liver glycogen disease (von Gierke's disease) as well as heterozygous carriers of the presumed causative genetic trait, was possible by determination of phosphorylated hexoses in circulating erythrocytes. They claimed that children with this disease, and their parents, have elevated levels of glucose6-phosphate and fructose-6-phosphate in their red blood cells. These findings have since been cited in other publications.2,3 If correct, this observation would have very important practical as well as theoretical implications. It would greatly simplify the diagnosis and study of this disease and would open up the possibility of its control through a eugenic approach. However, a disturbing feature of the report of Hsia and Kot

First Page Preview View Large
First page PDF preview
First page PDF preview